Posts Archive

NCT03848845: Phase 1/2: Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in...

(LINKER-MM1) RRMM First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma The primary objectives...

CEPHEUS Study MMY3019 A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE,...

CARTITUDE-1 Ciltacabtagene Autoleucel autologous bi-epitope BCMA-targeted CAR T cells JNJ-68284528 LCAR-B38M cilta-cel The purpose of the...

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma Study CC-93269-MM-001...

NCT03489525: Phase 1: MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228) The purpose of this study is to assess...

PLEIADES study A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimen MMY2040...

NCT03435796: Phase 2/3: Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells Long-Term Follow-up Protocol for...

CANOVA TRIAL t(11;14)-positive Relapsed or Refractory Multiple Myeloma. A Study of Venetoclax and Dexamethasone Compared With...

MonumenTAL-1 study A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific...

NCT03544281: Phase 2: To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in...

DREAMM 2 Relapsed & Refractory Multiple Myeloma A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants...

COLUMBA study A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory...

The APOLLO study EMN14/54767414MMY3013 Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed...

Phase 3 CANDOR study Dara-Kd Kd Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple...

OCEAN NCT03151811: Phase 3: A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to...

IMROZ Study NCT03319667 Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not...

NCT03374085: Phase 1/2: CC-92480 Monotherapy and with Dex in Relapsed / Refractory Multiple Myeloma A Safety, PK and Efficacy Study of...

NCT03275103: Phase 1 - Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) A Phase...